|
Volumn 7, Issue 280, 2015, Pages
|
Immunotherapy: Making the case for precision medicine
|
Author keywords
[No Author keywords available]
|
Indexed keywords
ABATACEPT;
BELATACEPT;
IPILIMUMAB;
MONOCLONAL ANTIBODY;
NIVOLUMAB;
PEMBROLIZUMAB;
RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT;
CANCER IMMUNOTHERAPY;
CELL ENGINEERING;
CELL THERAPY;
CLINICAL MEDICINE;
DENDRITIC CELL;
EDITORIAL;
HEALTH CARE;
HUMAN;
IMMUNE RESPONSE;
IMMUNOLOGICAL TOLERANCE;
IMMUNOREGULATION;
IMMUNOTHERAPY;
INTERDISCIPLINARY RESEARCH;
MEDICAL LITERATURE;
MEDICAL RESEARCH;
MESENCHYMAL STEM CELL;
MOLECULAR MECHANICS;
PERSONALIZED MEDICINE;
PRECISION MEDICINE;
PRIORITY JOURNAL;
REGULATORY T LYMPHOCYTE;
SENSITIVITY AND SPECIFICITY;
TREATMENT INDICATION;
HUMANS;
IMMUNE TOLERANCE;
IMMUNOTHERAPY;
PRECISION MEDICINE;
|
EID: 84925624642
PISSN: 19466234
EISSN: 19466242
Source Type: Journal
DOI: 10.1126/scitranslmed.aaa9846 Document Type: Editorial |
Times cited : (18)
|
References (10)
|